Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and Glatiramer Acetate

Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab

“…14 Natalizumab has also been found to be associated with reduced fatigue as compared with other disease-modifying therapies after longer-term use. 25 In the current study, improvement in fatigue scores was seen in patients with and without a recent relapse and in patients who were and were not using although our data suggest otherwise. In patients with MS, fatigue and cognition may worsen with time.…”

“…13,14,24,25 ENER-G is the largest prospective study to evaluate fatigue and cognition during natalizumab treatment, and to examine correlations between the two. Both fatigue and cognitive decline can be debilitating for MS patients.…”

Inflammation and the Silent Sequelae of Stroke

“…Other pharmacologic interventions using drugs that modulate the immune response could also be considered to treat PSF. For instance, treatment with natalizumab, which inhibits lymphocytes and monocytes, is associated with decreased fatigue in patients with MS [130]. This same drug is now being explored as a therapy for acute stroke, and assessing PSF in randomized controlled trials that evaluate acute stroke therapeutics may provide insight into the etiology, as well as the treatment, of PSF.…”

Multiple Sclerosis Symptom Recrudescence at the End of the Natalizumab Dosing Cycle

“…1 Furthermore, some natalizumab-treated patients experience subjective improvement in functional status, mood, fatigue level, and cognitive function. [2][3][4][5][6] Natalizumab is administered as a 300-mg intravenous infusion every 4 weeks. The mean half-life of natalizumab in MS patients is 11 days (SD 4 days).…”